06 June 2020 It will not only be a new factory, announced by the company as the most modern and one of the largest in the Group, but according to Menarini's intentions, "it will mark Italy's desire to start running again" and will have a name linked to the revitalization of the country.

The new Menarini Group site, which will be built in the Florentine area, will be a smart manufacturing plant, with innovative production technologies and automation and digitalization systems in line with the Industry 4.0 program with important environmental sustainability objectives.

Employees choose the name
The plant will have an annual production capacity of about 100 million packs, corresponding to about 3 billion tablets and will impress the desire for revitalization that gave it life, thanks to a particular initiative: "This plant will have a name, a little 'as a child - explain in fact Lucia and Alberto Giovanni Aleotti, shareholders and members of the Menarini Board - Our employees will choose it. A name that summarizes the courage, the will and the heart of Italy that wants to get up and team up in the most difficult moments ".

Economic results
The Menarini Group, which recently announced the purchase offer on the US biotech Stemline, closed 2019 with growing accounts compared to 2018. Turnover reached € 3 billion and € 800 million (€ 3,793 million), up 3.2% on 2018, and the Ebitda is 492 million. Growth was driven by international markets despite the patent expiration of Adenuric (febuxostat), a drug for hyperuricemia.

"The year that ended was obviously not affected by the Covid crisis, and saw Menarini increase its presence abroad and strengthen its governance with the appointment, in September, of the Group CEO, Elcin Barker Ergun. Today the turnover 77% of the total is international thanks to the dedication and commitment of our employees who bring the quality of Menarini drugs to the world ", comments Eric Cornut, President of the Menarini Group.